Basilea Pharmaceutica : Updated April 3, 2024

Creating anti-infective

opportunities

"Patients are at the heart of what we do"

Investor presentation

April 3, 2024

Table of contents

• Executive summary
• Portfolio
• • Antifungals
  • • Cresemba® (isavuconazole)
    • Fosmanogepix
    • BAL2062
  • Antibiotic
  • • Zevtera® (ceftobiprole)
    • Tonabacase
• Financials & Outlook
• Appendix

Creating anti-infective opportunities

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

2

Executive summary

Experienced leadership team

Creating anti-infective opportunities

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

4

At a glance

• Focus on the treatment of severe bacterial and fungal infections
• Recognized ability to establish and manage partnerships in both the development and commercial phase
• Cresemba® and Zevtera® - two revenue generating hospital anti-infective brands
• Commercial products complemented by clinical and preclinical programs, including
• • Fosmanogepix, a phase-3-readybroad-spectrum antifungal
  • BAL2062, an antifungal for the potential treatment of invasive aspergillosis
  • Tonabacase, an endolysin antibacterial for the potential treatment of severe staphylococcal infections
• Profitable biotech company listed on SIX Swiss Stock Exchange, SIX: BSLN
• Located in the Basel area life sciences hub, Switzerland

Creating anti-infective opportunities

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

5

Innovative anti-infective pipeline

1. The registration status and approved indications may vary from country to country.
2. Formerly GR-2397
3. Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
4. Exclusive option to in-license upon completion of preclinical profiling

Creating anti-infective opportunities

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

6

Global coverage - Cresemba®

Over 100 countries covered by partnerships

Creating anti-infective opportunities

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

7

The company we keep - Established strong partnerships

Double-digit percentage royalties on sales by license partners

	Participation
	in sales of
	distribution
	partners
	through
>CHF 1 bn	transfer price
in potential
milestones
remaining

>CHF 355 mn

upfront and

milestone payments received

Creating anti-infective opportunities

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

8

Antifungal

Cresemba® (isavuconazole)

Invasive mold infections

The market - Invasive fungal infections

• Severe, potentially life-threatening infections mainly affecting immunocompromised patients
• An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens
• Rising number of immunocompromised patients (cancer and transplantations) driving therapeutic demand
• Mucorales infections on the rise - doubled from 2000 to 2013
• Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents

**Kullberg/Arendrup N Engl J Med 2015, Baddley Clin Infect Dis 2010, Roden Clin Infect Dis 2005, Greenberg Curr Opin Infect Dis 2004.

Creating anti-infective opportunities

Proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution

10